Trial
NCT01794845
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Miami
Collaborators
—
Condition
Squamous Cell Carcinoma
Intervention
Erbitux
Why stopped
Early termination due to lack of efficacy (overall response)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-11